HUE050913T2 - Kezelési eljárás a szem állapotának javítására nyújtott leadású gyógyszer implantátummal - Google Patents

Kezelési eljárás a szem állapotának javítására nyújtott leadású gyógyszer implantátummal

Info

Publication number
HUE050913T2
HUE050913T2 HUE14805768A HUE14805768A HUE050913T2 HU E050913 T2 HUE050913 T2 HU E050913T2 HU E14805768 A HUE14805768 A HU E14805768A HU E14805768 A HUE14805768 A HU E14805768A HU E050913 T2 HUE050913 T2 HU E050913T2
Authority
HU
Hungary
Prior art keywords
eye
condition
improve
sustained release
treatment procedure
Prior art date
Application number
HUE14805768A
Other languages
English (en)
Hungarian (hu)
Inventor
Jane-Guo Shiah
Rahul Bhagat
Wendy M Blanda
Thierry Nivaggioli
Lin Peng
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52001114&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE050913(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of HUE050913T2 publication Critical patent/HUE050913T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts, ocular implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
HUE14805768A 2013-11-15 2014-11-14 Kezelési eljárás a szem állapotának javítására nyújtott leadású gyógyszer implantátummal HUE050913T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361904887P 2013-11-15 2013-11-15

Publications (1)

Publication Number Publication Date
HUE050913T2 true HUE050913T2 (hu) 2021-01-28

Family

ID=52001114

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14805768A HUE050913T2 (hu) 2013-11-15 2014-11-14 Kezelési eljárás a szem állapotának javítására nyújtott leadású gyógyszer implantátummal

Country Status (24)

Country Link
US (2) US20150140062A1 (enExample)
EP (2) EP3714875A1 (enExample)
JP (2) JP6675307B2 (enExample)
KR (3) KR20240058976A (enExample)
CN (1) CN105764517A (enExample)
AU (4) AU2014348369B2 (enExample)
CA (1) CA2929689A1 (enExample)
CL (1) CL2016001167A1 (enExample)
CY (1) CY1123344T1 (enExample)
DK (1) DK3068403T3 (enExample)
ES (1) ES2819215T3 (enExample)
HU (1) HUE050913T2 (enExample)
IL (2) IL245548A0 (enExample)
MX (2) MX2016006334A (enExample)
MY (1) MY176039A (enExample)
NZ (1) NZ719953A (enExample)
PH (1) PH12016500869A1 (enExample)
PL (1) PL3068403T3 (enExample)
PT (1) PT3068403T (enExample)
RU (1) RU2690841C1 (enExample)
SG (1) SG10201809363SA (enExample)
SI (1) SI3068403T1 (enExample)
UA (1) UA122117C2 (enExample)
WO (1) WO2015073895A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115337254A (zh) * 2015-07-23 2022-11-15 爱瑞制药公司 用于治疗眼病的玻璃体内药物递送系统
JP2019534063A (ja) 2016-09-02 2019-11-28 エンビシャ セラピューティクス インコーポレイテッド インプラントアプリケータ
MX2020012458A (es) 2018-05-24 2021-04-28 Celanese Eva Performance Polymers Llc Dispositivo implantable para liberacion sostenida de un compuesto de farmaco macromolecular.
US11689849B2 (en) 2018-05-24 2023-06-27 Nureva, Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
US11690806B2 (en) 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
IL299769A (en) * 2020-07-16 2023-03-01 Ocular Therapeutix Inc Ocular insert containing a glucocorticoid
WO2022231930A1 (en) 2021-04-26 2022-11-03 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
WO2002043785A2 (en) 2000-11-29 2002-06-06 Oculex Pharmaceuticals, Inc. Intraocular implants for preventing transplant rejection in the eye
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US20050244500A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intravitreal implants in conjuction with photodynamic therapy to improve vision
US20090082321A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
CA2827082A1 (en) * 2011-02-11 2012-08-16 Psivida Us, Inc. Methods of treating macular edema using antiedema therapeutics

Also Published As

Publication number Publication date
AU2014348369A1 (en) 2016-06-09
RU2690841C1 (ru) 2019-06-06
CA2929689A1 (en) 2015-05-21
WO2015073895A1 (en) 2015-05-21
US20250319031A1 (en) 2025-10-16
CY1123344T1 (el) 2021-12-31
AU2024205640B2 (en) 2025-10-23
EP3714875A1 (en) 2020-09-30
IL245548A0 (en) 2016-06-30
PT3068403T (pt) 2020-09-18
SG10201809363SA (en) 2018-11-29
KR20220082934A (ko) 2022-06-17
MX2016006334A (es) 2016-09-06
EP3068403B2 (en) 2025-12-03
AU2022204607A1 (en) 2022-07-21
MY176039A (en) 2020-07-22
KR20160085847A (ko) 2016-07-18
KR20240058976A (ko) 2024-05-07
CN105764517A (zh) 2016-07-13
PH12016500869B1 (en) 2016-07-04
PH12016500869A1 (en) 2016-07-04
JP2016538292A (ja) 2016-12-08
MX2022002306A (es) 2022-03-25
NZ719953A (en) 2022-01-28
KR102475746B1 (ko) 2022-12-08
SI3068403T1 (sl) 2020-11-30
CL2016001167A1 (es) 2017-01-06
JP2020055862A (ja) 2020-04-09
EP3068403A1 (en) 2016-09-21
US20150140062A1 (en) 2015-05-21
DK3068403T3 (da) 2020-09-07
RU2016119132A (ru) 2017-12-20
UA122117C2 (uk) 2020-09-25
AU2024205640A1 (en) 2024-08-29
JP6675307B2 (ja) 2020-04-01
JP7022735B2 (ja) 2022-02-18
AU2020204362A1 (en) 2020-07-23
AU2014348369B2 (en) 2020-04-02
IL290837A (en) 2022-04-01
ES2819215T3 (es) 2021-04-15
PL3068403T3 (pl) 2021-01-11
EP3068403B1 (en) 2020-06-17

Similar Documents

Publication Publication Date Title
PL3424955T3 (pl) Metoda wytwarzania koniugatu przeciwciało-lek anty-trop2
HUE071324T2 (hu) Szívbillentyû protézis
BR112015002548A2 (pt) máscara ocular
LT2981255T (lt) Empagliflozino terapiniai panaudojimo būdai
HRP20190101T1 (hr) Terapeutske uporabe empagliflozina
HUE042528T2 (hu) Okuláris készítmények a szem hátsó szegmenséhez történõ gyógyszer-kijuttatáshoz
HUE056006T2 (hu) Kombináció Parkinson-kór kezelésére
EP3878404C0 (en) ARTIFICIAL VASCULAR GRAFT
IL247354A0 (en) Treatment of conditions associated with hyperinsulinaemia
IL290837A (en) Methods for the treatment of ocular diseases using a continuous drug delivery implant
DK3470018T3 (da) Kryokonservering af levedygtige menneskehudssubstitutter
PL2959903T3 (pl) Lek do leczenia chorób oczu
LT2958624T (lt) Transplantuotų pacientų transplantanto prieš šeiminiką ligos gydymas
PL2808053T3 (pl) Biokompatybilna elektroda wszczepialna
EP2773419A4 (en) IMPLANTABLE MEDICAL PASSIVE ELECTRODE
HUE051295T2 (hu) Módosított fibroblaszt növekedési faktorok-1 szembetegségek kezelésére
IL240222A0 (en) Treatment of the disease with nano-fibers of poly-n-acetylglucosamine
FR2998474B1 (fr) Implant intraoculaire trans-irien
EP2839068A4 (en) Clothes treatment apparatus
IL242694B (en) Human monocyte sub-population for treatment of eye diseases and disorders
DK2976101T3 (da) Behandlingsfremgangsmåde
GB201421052D0 (en) Artificial tissue
FR3008884B1 (fr) Prothese implantable
DK3041506T3 (da) Behandlingsfremgangsmåde
DK3011760T3 (da) Mellemøretransducer med biokompatibel implanterbar klæbepude